AbbVie presents nine-year data validating long-term benefits of fixed-duration Leukemia treatment
AbbVie (NYSE:ABBV) announced long-term follow-up results from its landmark Phase 3 CLL14 clinical trial, reinforcing the durable efficacy of its BCL-2 inhibitor Venclexta (venetoclax) when used as a fixed-duration therapy.
The final analysis, presented at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, tracked previously untreated chronic lymphocytic leukemia (CLL) patients over a nine-year period, demonstrating extended time off-treatment for individuals with coexisting medical conditions.
The trial, conducted in partnership with the German CLL Study Group, randomized 432 patients to evaluate a 12-month fixed-duration regimen of Venclexta combined with obinutuzumab against a standard chlorambucil plus obinutuzumab chemoimmunotherapy control arm.
Following a median follow-up of 9.2 years, patients treated with the Venclexta-based combination achieved a median progression-free survival (PFS) of 6.4 years, doubling the 3.2 years recorded in the control group.
Furthermore, the data highlighted a median time to next treatment (TTNT) of 7.6 years for the Venclexta arm.
This metric underscores the sustained durability of the response, allowing patients an extended treatment-free interval after completing the initial one-year regimen.
The final safety profile proved consistent with prior trial readouts, characterized primarily by manageable hematologic adverse events such as neutropenia.
Management noted that these longitudinal findings validate the foundational role of Venclexta in frontline CLL care, offering highly predictable disease control without the burden of continuous long-term dosing.
